AJR Join ARRS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spinosa, D. J.
Right arrow Articles by McConnell, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spinosa, D. J.
Right arrow Articles by McConnell, K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
AJR 2001; 176:1305-1311
© American Roentgen Ray Society


Safety of CO2- and Gadodiamide-Enhanced Angiography for the Evaluation and Percutaneous Treatment of Renal Artery Stenosis in Patients with Chronic Renal Insufficiency

David J. Spinosa1, Alan H. Matsumoto1, J. Fritz Angle1, Klaus D. Hagspiel1, Dorothy Cage1, Eric A. Bissonette2, K. G. Koenig3, C. R. Ayers3 and K. McConnell4

1 Department of Radiology, University of Virginia Health System, Lee St., Box 170, Charlottesville, VA 22908.
2 Department of Health Evaluation Sciences, University of Virginia Health System, Charlottesville, VA 22908.
3 Department of Medicine, University of Virginia Health System, Charlottesville, VA 22908.
4 Department of Medicine, Martha Jefferson Hospital, Locust Ave., Charlottesville, VA 22901.

OBJECTIVE. The objective of our study was to evaluate the safety of CO2 and gadodiamide angiography for diagnosing and percutaneously treating renal artery stenosis in patients with chronic renal insufficiency and presumed ischemic nephropathy.

SUBJECTS AND METHODS. One hundred forty-six consecutive patients with chronic renal insufficiency (serum creatinine > 1.5 mg/dL) were examined for renal artery stenosis using CO2 and gadodiamide as the angiographic contrast agents. If renal artery stenosis was detected, percutaneous balloon angioplasty with or without stenting was performed. In patients for whom 48-hr creatinine levels were available, we performed an analysis to determine the incidence of contrast-involved nephropathy (increase in serum creatinine of 0.5 mg/dL at 48 hr without identifiable cause). Major complications were reported up to 1 week, and mortality was reported up to 30 days after the procedure.

RESULTS. Ninety-five patients had serum creatinine levels available at 48 hr. An increase in creatinine of greater than 0.5 mg/dL at 48 hr occurred in three patients (3.2%), presumably caused by CO2, by gadodiamide, or by both. Neither diabetes nor the degree of preexisting chronic renal insufficiency was a predictor of worsening renal function 48 hr after the procedure. The volumes of CO2 and gadodiamide used for diagnostic studies alone versus the volume used for interventional studies was not significantly different (for CO2, p = 0.09; for gadodiamide, p = 0.30). Eleven major complications occurred in eight patients (5.5%). Two deaths (1.4%) occurred within 30 days. One death was due to cholesterol embolization and the other was not believed to be related to the procedure.

CONCLUSION. Angiography and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency and suspected ischemic nephropathy can be performed relatively safely using CO2 and gadodiamide as angiographic contrast agents without an increased risk of complications. Contrast-induced nephropathy potentially occurred in 3.2% of patients. Neither the degree of underlying renal insufficiency nor diabetes was a risk factor for predicting a greater likelihood of renal function worsening at 48 hr of follow-up. The volumes of CO2 and gadodiamide used in this study did not result in an increased risk of contrast-involved nephropathy.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
G. C. Kane, A. W. Stanson, D. Kalnicka, D. W. Rosenthal, C. U. Lee, S. C. Textor, and V. D. Garovic
Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes
Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1233 - 1240.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
E. Balk, G. Raman, M. Chung, S. Ip, A. Tatsioni, A. Alonso, P. Chew, S. J. Gilbert, and J. Lau
Effectiveness of Management Strategies for Renal Artery Stenosis: A Systematic Review
Ann Intern Med, December 19, 2006; 145(12): 901 - 912.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
P. C. Mannebach, R. S. Dieter, and D. S. Marks
Use of Gadolinium-Based Angiography for Renal Artery Stenting in a Patient With Renal Insufficiency: A Case Report
Angiology, August 1, 2006; 57(4): 526 - 529.
[Abstract] [PDF]


Home page
PERSPECT VASC SURG ENDOVASC THERHome page
J. Ayerdi and K. J. Hodgson
Balloon Angioplasty and Stenting for Renovascular Occlusive Disease
Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2004; 16(1): 25 - 38.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Roentgen Ray Society.